Vincristine pharmacokinetics after repetitive dosing in children

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 3, 1999, Pages 203-209

  Gidding, C E M ^a   Meeuwsen De Boer, G J ^a   Kamps, W A ^a   De Graaf, S S N ^a   Koopmans, P ^b   Uges, D R A ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Children; Pharmacokinetics; Repetitive dosing; Vincristine

Indexed keywords

ASPARAGINASE; BISACODYL; COTRIMOXAZOLE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYES THEOREM; CHILD; CLINICAL ARTICLE; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ELECTROCHEMISTRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; STEADY STATE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LYMPHOMA, NON-HODGKIN; VINCRISTINE; WILMS TUMOR;

EID: 0032800705     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050968     Document Type: Article

References (39)

1. 1. Bender RA, Castle MC, Margileth DA, Oliverio VT (1977) The pharmacokinetics of [3H]-vincristine in man. Clin Pharmacol Ther 22: 430
2. 2. Bloemhof H, Van Dijk KN (1991) Sensitive method for the determination of vincristine in human serum by high-performance liquid chromatography after on-line column-extraction. J Chromatogr 572: 171
3. 3. Brosen K (1990) Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin pharmacokinet 18: 220
4. 4. Cooper KO, Reik LM, Jayyosi Z, Bandiera S, Kelley M, Ryan DE, Daniel R, McCluskey SA, Levin W, Thomas PE (1993) Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats. Arch Biochem Biophys 301: 345
5. 5. Crom WR, De Graaf SSN, Synold T, Uges DRA, Bloemhof H, Rivera G, Christensen ML, Mahmoud H, Evans WE (1994) Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 125: 642
6. 6. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9: 739
7. 7. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Methods Programs Biomed 9: 115
8. 8. De Graaf SSN, Bloemhof H, Vendrig DEMM, Uges DRA (1995) Vincristine disposition in children with acute lymphoblastic leukemia. Med Ped Oncol 24: 235
9. 9. De Smet M, Van Belle SJP, Storme GA (1985) High-performance liquid chromatographic determination of Vinca-alkaloids in plasma and urine. J Chromatogr 345: 309
10. 10. Desai ZR, Van den Berg HW, Bridges JM, Shanks RG (1982) Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 8: 211
11. 11. Donigian DW, Owellen RJ (1973) Interaction of vinblastine, vincristine and colchicine with serum proteins. Biochem Pharmacol 22: 2113
12. 12. Faber ED (1995) Cytochroom-P450-isoenzymen; bron van veel interacties. Pharm Sel 11: 73
13. 13. Green DM, Thomas PRM, Schochat S (1995) The treatment of Wilms tumor; results of the National Wilms Tumor Studies. Hematol Oncol Clin North Am 9: 1267
14. 14. Houghton JA, Torrance PM, Houghton PJ (1983) Chromatographic analysis of vinca alkaloids in human neoplastic tissues and host (mouse) tissues after injection in vivo or after incubation in vitro. Anal Biochem 134: 450
15. 15. Jackson DV, Sethi VS, Spurr CL, McWhorter JM (1981) Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 41: 1466
16. 16. Jackson DV, Sethi VS, Spurr CL, White DR, Richards FI, Stuart JJ, Muss HB, Cooper MR, Castle MC (1981) Pharmacokinetics of vincristine infusion. Cancer Treat Rep 65: 1043
17. 17. Katz D, Azen SP, Schumitzky A (1981) Bayesian approach to the analysis of nonlinear models: implementation and evaluation. Biochemistry 37: 137
18. 18. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM (1995) The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15: 387
19. 19. McCune JS, Lindley C (1997) Appropriateness of maximumdose guidelines for vincristine. Am J Health Syst Pharm 54: 1755
20. 20 Nelson RL (1982) The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med Ped Oncol 10: 115
21. 21. Nelson RL, Dyke RW, Root MA (1980) Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 7: 17
22. 22. Owellen RJ, Hartke CA, Hains FO (1977) Pharmacokinetics and metabolism of vincristine in humans. Cancer Res 37: 2597
23. 23. Rahmani R, Zhou XJ (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 17: 269
24. 24. Ramirez J, Ogan K, Ratain MJ (1997) Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Cancer Chemother Pharmacol 39: 286
25. 25. Ratain MJ, Vogelzang NJ, Sinkule JA (1987) Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther 41: 61
26. 26. Riehm H, Lampert F, Schellong G, Gadner H, Zintl F, Pluess J, Henze G, Niethammer D, Reiter A, Schrappe M (1997) Risk-oriented treatment of childhood ALL: an update of multicenter trial ALL-BFM 90. Med Ped Oncol 29: 438
27. 27. Rowland M, Tozer TN (1995) Variability. In: Rowland M, Tozer TN (eds) Clinical pharmacokinetics; concepts and applications. Williams and Wilkins, Baltimore, p 203
28. 28. Schumacher GE, Barr JT (1984) Pharmacokinetics in drug therapy: bayesian approaches in pharmacokinetic decision making. Clin Pharmacol 3: 525
29. 29. Schwartz CL, Smith J, Piantadosi S (1996) Effect of vincristine dose on outcome in childhood ALL. Proc Am Soc Clin Oncol 15: 366
30. 30. Sethi VS, Jackson DV, White CT, Richards FI, Stuart JJ, Muss HB, Cooper MR, Spurr CL (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41: 3551
31. 31. Sethi VS, Kimball JC (1981) Pharmacokinetics of vincristine sulfate in children. Cancer Chemother Pharmacol 6: 111
32. 32. Sheiner LB, Beal SL (1982) Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-bayesian methods. J Pharmacol Sci 71: 1344
33. 33. Tew KD, Houghton PJ, Houghton JA (1993) Modulation of p-glycoprotein-mediated multidrug resistance. In: Tew KD (ed) Preclinical and clinical modulation of anticancer drugs. CRC Press, Forida, p 125
34. 34. Touw DJ, Breimer DD (1997) Het cytochroom P450-enzymsysteem; een familie met acties, reacties en interacties. Pharma Weekbl 132: 948
35. 35. Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG (1982) The pharmacokinetics of vincristine in man; reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 8: 215
36. 36. Van Warmerdam LJC, Van den Bemt BJF, Ten Bokkel Hunink WW, Maes RAA, Beijnen JH (1995) Dose individualisation in cancer chemotherapy: pharmacokinetic and pharmacodynamic relationships. Cancer Res Ther Control 4: 277
37. 37. Vendrig DEMM, Teeuwsen J, Holthuis JJM (1988) Analysis of vinca alkaloids in plasma and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr 424: 83
38. 38. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem Pharmacol 45: 853
39. 39. Zhou-Pan XR, Sérée E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 53: 5121